Stellar Pharmaceuticals Inc.

Stellar Pharmaceuticals Inc.

January 07, 2005 13:52 ET

Stellar Pharmaceuticals Inc. Appoints Investor Relations Firms


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: STELLAR PHARMACEUTICALS INC.

TSX VENTURE SYMBOL: SLX
OTC Bulletin Board SYMBOL: SLXCF

JANUARY 7, 2005 - 13:52 ET

Stellar Pharmaceuticals Inc. Appoints Investor
Relations Firms

LONDON, ONTARIO--(CCNMatthews - Jan. 7, 2005) - Stellar Pharmaceuticals
Inc. (TSX VENTURE:SLX)(OTCBB:SLXCF), a Canadian pharmaceutical developer
and marketer of high quality, cost-effective products for select health
care markets, announced today that it has retained The Equity Group Inc.
to provide investor relations services to the company, and FF Investors,
LLC to assist the company with developing strategic relations for the
company.

The Equity Group Inc.

The Equity Group was founded in 1974 and is a full service investor
relations firm, providing services principally to micro through mid-cap
public companies listed on the NASDAQ®, American and New York Stock
Exchanges. The services The Equity Group provides include financial
community and media relations, editorial services and interactive
communications, as well as administrative, consulting and advisory
services.

The Equity Group is based in New York, New York and has no direct or
indirect relationship with Stellar.

The agreement between Stellar and The Equity Group provides for one-year
terms which renew automatically, unless otherwise terminated in
accordance with the terms of the agreement. Pursuant to the terms of the
agreement The Equity Group will be paid a monthly fee of US$6,000. In
addition, The Equity Group has been granted options to acquire 250,000
common shares in the capital of Stellar (as set forth in a press release
dated December 3, 2004). The services to be provided include, media
relations, website consulting, arranging investor presentations,
assisting with the drafting and dissemination of press releases and
assisting with the development and editing of Stellar's road show
materials.

FF Investors, LLC

FF Investors LLC is a private investment and strategic relations company
based in North Palm Beach, Florida and has no direct or indirect
relationship with Stellar.

The agreement between Stellar and FF Investors, LLC expires on January
4, 2007. Pursuant to the terms of the agreement FF Investors, LLC has
been granted options to acquire 120,000 common shares in the capital of
Stellar (as set forth in a press release dated December 3, 2004). The
services to be provided by FF Investors, LLC will include, among other
things, (i) coordinating on behalf of the Corporation, the dissemination
of marketing information approved by the Corporation, (ii) scheduling
introductory calls and initial meetings with various analysts and
institutional investors and (iii) maintaining on-going relationships and
discourse with respect to the Corporation.

FF Investors, LLC owns or has the right to acquire 520,000 common shares
of Stellar (inclusive of the above disclosed options).

Stellar has developed and is marketing three products in Canada based on
its core polysaccharide technology: NeoVisc®, for the treatment of
osteoarthritis, Uracyst® and the Uracyst® Test Kit, Stellar's
patented technology for the diagnosis and treatment of Interstitial
Cystitis (IC), an inflammatory disease of the urinary bladder wall.
Stellar also has in-licensing agreements for Skelite™ a proprietary
synthetic bone-grafting product and NMP22® BladderChek®, a
proteomics-based diagnostic test for the diagnosis and monitoring of
bladder cancer which are expected to positively impact sales in 2004.

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Readers are cautioned
not to place undue reliance on these forward-looking statements. Actual
results may differ materially from those indicated by these
forward-looking statements as a result of risks and uncertainties
impacting the Company's business including increased competition; the
ability of the Company to expand its operations, to attract and retain
qualified professionals, technological obsolescence; general economic
conditions; and other risks detailed time to time in the Company's
filings

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Stellar Pharmaceuticals Inc.
    Peter Riehl
    President & CEO
    (800) 639-0643 or (519) 434-1540
    or
    Stellar Pharmaceuticals Inc.
    Arnold Tenney
    Chairman
    (416) 587-3200
    or
    The Equity Group Inc.
    Devin Sullivan
    (212) 836-9608
    or
    The Equity Group Inc.
    Adam Prior
    (212) 836-9606
    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this release.